GLP1R and metabolic dysfunction-associated steatohepatitis: Zhou et al. reported that injection of exenatide, a GLP-1 agonist, significantly reduced diethylnitrosamine-induced hepatocellular carcinoma in both low-fat low-carbohydrate- and high-fat high-carbohydrate-fed mice, which suggests that exenatide prevented hepatocarcinogenesis independent of obesity and NASH [42].